Evidence map›Paper›PMID 42458315›Full record

ArticleBMC cancer2026

FOLFOX-HAIC plus regorafenib for the treatment of unresectable colorectal liver metastases refractory to first and second-line systemic chemotherapy.

Jiacheng Liu, Songlin Song, Wei Yao, Yanqiao Ren, Yiming Liu, Chuansheng Zheng, Bin Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiacheng Liu *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Songlin Song *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wei Yao *Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yanqiao RenDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yiming LiuDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. lymtongji@163.com.
Chuansheng ZhengDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. hqzcsxh@sina.com.
Bin LiangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. bliang@hust.edu.cn.ORCID http://orcid.org/0000-0002-6130-8629

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic arterial infusion chemotherapy (HAIC) is a potentially attractive locoregional therapy for patients with unresectable colorectal liver metastases (CRLM). This study aimed to evaluate the safety and efficacy of FOLFOX-HAIC plus regorafenib in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy.

methodsA total of 35 patients with unresectable CRLM who underwent FOLFOX-HAIC plus regorafenib between July 2020 and January 2023 were included in this retrospective study. The objective response rate (ORR), disease-controlled rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse event were assessed. Factors affecting OS were analyzed.

resultsKaplan-Meier curves showed that the median OS

conclusionsFOLFOX-HAIC plus regorafenib might be beneficial and tolerable in the treatment of unresectable CRLM refractory to first and second-line systemic chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsLiver NeoplasmsPhenylurea CompoundsPyridinesAdultAgedFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinMaleMiddle AgedOrganoplatinum CompoundsFluorouracilLeucovorinOrganoplatinum CompoundsPhenylurea CompoundsPyridinesregorafenibColorectal liver metastasesHepatic arterial infusion chemotherapyOverall survivalProgression-free survivalRegorafenib

Identifiers

PMID42458315
PMCPMC13679240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.